Beltran Lab

Publications

Found 69 results
Journal Article
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Beltran H, Antonarakis ES, Morris MJ, Attard G.  2016.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.. Am Soc Clin Oncol Educ Book. (35):131-41.
Beltran H.  2013.  DNA mismatch repair in prostate cancer.. J Clin Oncol. 31(14):1782-4.
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopolou E, Chakravarthi BV, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 3(22):298-305.
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P et al..  2013.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.. Nat Biotechnol. 31(11):1023-31.
Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y et al..  2013.  Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.. Neoplasia. 15(7):761-72.
Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londono-Vallejo A et al..  2015.  CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities.. Oncotarget. 6(14):11994-2008.
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia . (1):1-10.
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V et al..  2018.  Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.. Eur Urol.
Beltran H, Tagawa ST, Park K, Macdonald T, Milowsky MI, Mosquera JMiguel, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):e386-9.
Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.  2012.  Challenges in recognizing treatment-related neuroendocrine prostate cancer.. J Clin Oncol. 30(36):386-9.
Davies AH, Beltran H, Zoubeidi A.  2018.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer.. Nat Rev Urol.
Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al..  2017.  Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer.
Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.
Chedgy ECp, Vandekerkhove G, Herberts C, Annala M, Donoghue AJ, Sigouros M, Ritch E, Struss W, Konomura S, Liew J et al..  2018.  Biallelic tumor suppressor loss and DNA repair defects in de novo small cell prostate cancer.. J Pathol.
Beltran H, Park K, Tagawa ST, Macdonald T, Nanus DM, Mosquera JMiguel, Rubin MA.  2012.  Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. J Clin Oncol. 30(5_suppl):120.
Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H et al..  2014.  Aggressive variants of castration-resistant prostate cancer.. Clin Cancer Res. 20(11):2846-50.
Tagawa ST, Beltran H.  2011.  Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.. Asian J Androl. 13(6):785-6.
Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y et al..  2017.  Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.. Cancer Cell. 32(6):792-806.e7.